SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q3 FY26 results · Oct–Dec 2025
SMS Pharmaceuticals reported revenue from operations of ₹210.45 crore (up 21.4% from Q3 FY25) and net profit of ₹23.47 crore (up 28.7% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 210.45 | 173.35 | +21.4% | 242.43 | −13.2% |
| Other income | 3.75 | 2.13 | +76.3% | 1.43 | +161.7% |
| Total income | 214.20 | 175.48 | +22.1% | 243.86 | −12.2% |
| Profit before share of associates & JVs and tax | 31.16 | 22.44 | +38.9% | 34.04 | −8.5% |
| Share of profit/(loss) of associates & JVs | 0.28 | 1.16 | 0.18 | ||
| Net profit for the period | 23.47 | 18.24 | +28.7% | 25.31 | −7.3% |
| EPS, basic (₹) | 2.59 | 2.15 | not comparable | 2.84 | −8.8% |
| Net margin (%) | 11.2 | 10.5 | 10.4 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 210.45 | 173.35 | +21.4% | 242.43 | −13.2% |
| Other income | 3.75 | 2.13 | +76.3% | 1.43 | +161.7% |
| Total income | 214.20 | 175.48 | +22.1% | 243.86 | −12.2% |
| Profit before tax | 31.31 | 22.53 | +39.0% | 34.06 | −8.1% |
| Net profit for the period | 23.34 | 17.17 | +35.9% | 25.14 | −7.2% |
| EPS, basic (₹) | 2.57 | 2.03 | not comparable | 2.82 | −8.9% |
| Net margin (%) | 11.1 | 9.9 | 10.4 |
Consolidated
- Filed with BSE
- 07 Feb 2026, 17:11 IST
- Board meeting
- 07 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Feb 2026, 17:11 IST
- Board meeting
- 07 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE